Inhibition of Acyl-CoA Cholesterol Acyltransferase by F12511 (Eflucimibe): Could it be a New Antiatherosclerotic Therapeutic?

MLA

López-Farré, Antonio José, et al. “Inhibition of Acyl-CoA Cholesterol Acyltransferase by F12511 (Eflucimibe): Could It Be a New Antiatherosclerotic Therapeutic?” Cardiovascular Therapeutics, vol. 26, no. 1, Spring 2008, pp. 65–74. EBSCOhost, https://doi.org/10.1111/j.1527-3466.2007.00030.x.

APA

López-Farré, A. J., Sacristán, D., Zamorano-León, J. J., San-Martín, N., & Macaya, C. (2008). Inhibition of Acyl-CoA Cholesterol Acyltransferase by F12511 (Eflucimibe): Could it be a New Antiatherosclerotic Therapeutic? Cardiovascular Therapeutics, 26(1), 65–74. https://doi.org/10.1111/j.1527-3466.2007.00030.x

Chicago

López-Farré, Antonio José, Daniel Sacristán, José J. Zamorano-León, Nuria San-Martín, and Carlos Macaya. 2008. “Inhibition of Acyl-CoA Cholesterol Acyltransferase by F12511 (Eflucimibe): Could It Be a New Antiatherosclerotic Therapeutic?” Cardiovascular Therapeutics 26 (1): 65–74. doi:10.1111/j.1527-3466.2007.00030.x.